(Information sent by the undersigned)
– MolecuLight’s pioneering fluorescence imaging technology is featured in a new study in the prestigious Burns journal.
Toronto, May 30, 2024 /PRNewswire/ — MolecuLight Inc., a global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, is celebrating the publication of a groundbreaking study in the prestigious Burns Journal. Graduated “Bacterial fluorescence imaging as a predictor of skin graft integration in burn wounds”., This study demonstrates the unprecedented ability of MolecuLight’s innovative technology to predict outcomes of skin graft integration in burn patients.
This study examined the predictive ability of molecular fluorescence imaging to assess the presence of bacteria associated with skin graft failure in burn wounds. The results revealed significant correlations (greater than 10.0) between the presence or absence of bacteria4 CFU/gr of tissue) in the graft bed immediately before skin grafting and graft failure or success.
The key findings of the study are as follows:
- Absence of fluorescent signals produced a graft absorption rate of 99.2% per cm.2Its presence reduced graft absorption rate to 27.9% per cm2.
- Fluorescence imaging predicts bacteria-associated graft loss with 98% specificity.
- A higher probability of graft success was observed in areas with negative fluorescence signals (99–100% negative predictive value).
- Standard swab specimens detect no bacterial growth at most graft sites and are currently used to determine graft suitability.
“These compelling results highlight the transformative impact of MolecuLight in treating burns, another area of injury where our technology is making a difference,” said Anil Amlani, CEO of MolecuLight Inc. Time data on the presence of bacteria, Moleculide’s fluorescence imaging technology ultimately led to improved patient outcomes, “Eliminating fluorescent signals at the graft site has the potential to improve adhesion. Acceptance.”
Doctor Eric Hanson-ViennaThe study’s lead author commented: “Our recent publication on fluorescence imaging and its use in split skin grafts is an important new contribution to the field in educating surgeons about the importance of this new technology. I am confident that this technology can improve graft protocols for burn patients and provide real-time The unique ability to acquire information provides critical data to make general informed decisions MolecuLight allows surgeons to act quickly on late microbiological samples when the graft bed is devoid of bacteria to determine whether the graft is ready.
The publication of this study in the prestigious Burns Journal reinforces MolecuLight’s commitment to improving wound care through cutting-edge technology and innovative, high-quality research. Through its ability to provide actionable information at the point of care, MolecuLight’s fluorescence imaging technology continues to revolutionize injury assessment and treatment worldwide in various fields of medicine.
MolecuLight Inc. About:
MolecuLight Inc. , is a privately held medical imaging company that develops and markets its proprietary fluorescent imaging platform technology in several medical markets. MolecuLight’s suite of commercial devices, MolecuLight Fluorescent Imaging Systems I:X Y DX™ and its components are portable imaging devices for real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States a Method of repayment There are two CPT codes for physician work on fluorescence imaging by ambulatory payment classification (APC) assignment for bacterial presence, location, and hospital outpatient department (HOPD) and ambulatory surgery centers (ASC). The company is commercializing its unique fluorescence imaging platform technology into other global markets, with associated unmet needs in food safety, consumer cosmetics and other key industrial markets.
For sales, media or other inquiries or more information, please get in touchCarolina WustoffMDGlobal Director of Medical Engagement and CommunicationsMolecuLight Inc.[email protected]T. +1.647.362.4684 www.moleculelight.com
Photo – https://mma.prnewswire.com/media/2423988…
View original content: https://www.prnewswire.com/news-releases/se-presenta-la-pionera-tecnologia-de-imagen-por-fluorescencia-de-moleculight-302158351.html
